National Institute for Health and Care Excellence

New life-extending treatment given the green light for people with rare form of bile duct cancer

NICE has recommended zanidatamab, also known as Ziihera and made by Jazz Pharmaceuticals, in final draft guidance for adults with HER2-positive advanced biliary tract cancer - a group of cancers ...
National Institute for Health and Care Excellence

Published guidance, NICE advice and quality standards

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...
The National Institute for Health and Care Excellence

‘Trojan horse’ treatment recommended for people with multiple myeloma

Around 1,600 people a year in England with multiple myeloma are set to benefit from a new treatment option after we recommended belantamab mafodotin (also known as Blenrep and made by GSK).
The National Institute for Health and Care Excellence

New take at home drug recommended for people with chronic lymphocytic leukaemia

NICE has recommended a new take‑at‑home tablet for some people with chronic lymphocytic leukaemia whose disease has returned after treatment. The draft guidance could give patients greater choice and ...
The National Institute for Health and Care Excellence

Have your say on NICE’s adoption of the new EQ-5D-5L value set

We have launched a public consultation on the proposed adoption of the new EQ-5D-5L value set which will help us to make more accurate assessments of how treatments improve health-related quality of ...
National Institute for Health and Care Excellence

Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection

Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
National Institute for Health and Care Excellence

Artificial intelligence (AI) technologies to help detect fractures on X-rays in urgent care: early value assessment

We have moved Health technology evaluation 20 to become HealthTech guidance 739. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme ...
National Institute for Health and Care Excellence

Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...
National Institute for Health and Care Excellence

Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under

Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under. There is a simple discount patient ...
National Institute for Health and Care Excellence

Parkinson’s disease in adults

This guideline covers diagnosing and managing Parkinson's disease in people aged 18 and over. It aims to improve care from the time of diagnosis, including monitoring and managing symptoms, providing ...
National Institute for Health and Care Excellence

Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes

Access to hybrid closed loop systems will be through a 5-year phased roll out in line with NHS England's implementation plan. For enquiries about cost-effective pricing contact ...
National Institute for Health and Care Excellence

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy

Evidence-based recommendations on axicabtagene ciloleucel (Yescarta) for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy. There is a managed access ...